AI Engines For more Details: Perplexity Kagi Labs You
Gastrointestinal Disorders:
Antispasmodic Effects:
Dosage and Administration:
Adverse Effects:
Contraindications and Precautions:
Drug Interactions:
Rank | Probiotic | Impact |
---|---|---|
species | Bacteroides uniformis | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
ADHD | 0.6 | 0.6 | |
Allergic Rhinitis (Hay Fever) | 1.5 | 0.6 | 1.5 |
Allergies | 1.8 | 1.3 | 0.38 |
Allergy to milk products | 1.2 | 0.9 | 0.33 |
Alzheimer's disease | 1.8 | 2.8 | -0.56 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.9 | 0.9 | 0 |
Ankylosing spondylitis | 1.9 | 1.2 | 0.58 |
Anorexia Nervosa | 0.3 | 1.2 | -3 |
Antiphospholipid syndrome (APS) | 0.6 | 0.3 | 1 |
Asthma | 1.2 | 0.3 | 3 |
Atherosclerosis | 1.5 | 1.5 | |
Atrial fibrillation | 1.2 | 2.1 | -0.75 |
Autism | 2.8 | 3.3 | -0.18 |
Autoimmune Disease | 0.6 | 0.6 | |
benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
Biofilm | 1.2 | 1.2 | |
Bipolar Disorder | 1.5 | 0.3 | 4 |
Brain Trauma | 0.6 | -0.6 | |
Breast Cancer | 0.6 | 0.6 | |
Cancer (General) | 0.6 | -0.6 | |
Carcinoma | 1.5 | 0.6 | 1.5 |
Celiac Disease | 1.2 | 0.9 | 0.33 |
Cerebral Palsy | 0.3 | 0.6 | -1 |
Chronic Fatigue Syndrome | 2.1 | 1.3 | 0.62 |
Chronic Kidney Disease | 1.7 | 1 | 0.7 |
Chronic Lyme | 0.3 | -0.3 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 0.6 | |
Chronic Urticaria (Hives) | 1.2 | 0.8 | 0.5 |
Coagulation / Micro clot triggering bacteria | 1.2 | 0.3 | 3 |
Cognitive Function | 0.6 | 0.6 | |
Colorectal Cancer | 2.4 | 1.2 | 1 |
Constipation | 1.2 | 1.2 | |
Coronary artery disease | 2.4 | 1.1 | 1.18 |
COVID-19 | 1.8 | 2.8 | -0.56 |
Crohn's Disease | 3 | 1.4 | 1.14 |
Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
cystic fibrosis | 1.2 | 0.3 | 3 |
d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
deep vein thrombosis | 1.5 | 0.6 | 1.5 |
Depression | 3 | 2.6 | 0.15 |
Eczema | 1.2 | 0.3 | 3 |
Endometriosis | 1.5 | 0.9 | 0.67 |
Epilepsy | 1.8 | 0.3 | 5 |
erectile dysfunction | 0.9 | 0.9 | |
Fibromyalgia | 0.7 | -0.7 | |
Functional constipation / chronic idiopathic constipation | 2.1 | 1.6 | 0.31 |
gallstone disease (gsd) | 2.4 | 2.4 | |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.3 | |
Generalized anxiety disorder | 2.1 | 0.3 | 6 |
Gout | 0.6 | 0.6 | |
Graves' disease | 0.6 | 0.6 | 0 |
Gulf War Syndrome | 0.3 | -0.3 | |
Halitosis | 0.3 | 0.3 | |
Hashimoto's thyroiditis | 1.2 | 0.8 | 0.5 |
Heart Failure | 2.4 | 0.8 | 2 |
Hidradenitis Suppurativa | 0.6 | 0.6 | |
High Histamine/low DAO | 0.6 | 0.3 | 1 |
hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | |
hyperglycemia | 1.2 | 0.3 | 3 |
Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
hypersomnia | 0.3 | -0.3 | |
hypertension (High Blood Pressure | 1.4 | 1.2 | 0.17 |
Hypoxia | 1.5 | 1.5 | |
IgA nephropathy (IgAN) | 0.6 | 1 | -0.67 |
Inflammatory Bowel Disease | 2.4 | 3.3 | -0.38 |
Insomnia | 0.3 | 0.9 | -2 |
Intelligence | 0.9 | 0.4 | 1.25 |
Intracranial aneurysms | 0.6 | 0.6 | |
Irritable Bowel Syndrome | 3 | 0.6 | 4 |
ischemic stroke | 1.2 | 1.2 | 0 |
Liver Cirrhosis | 2.7 | 1.5 | 0.8 |
Long COVID | 1.8 | 1.5 | 0.2 |
Lung Cancer | 0.9 | 0.3 | 2 |
Lymphoma | 0.6 | 0.6 | |
Mast Cell Issues / mastitis | 0.6 | 0.3 | 1 |
ME/CFS with IBS | 0.3 | -0.3 | |
ME/CFS without IBS | 0.6 | 0.3 | 1 |
Metabolic Syndrome | 3.2 | 1.2 | 1.67 |
Mood Disorders | 2.4 | 2.6 | -0.08 |
Multiple Sclerosis | 1.2 | 1.9 | -0.58 |
Multiple system atrophy (MSA) | 0.3 | -0.3 | |
myasthenia gravis | 0.6 | 0.6 | |
neuropathic pain | 0.3 | -0.3 | |
Neuropathy (all types) | 0.6 | -0.6 | |
neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.2 | 1.1 | 1 |
NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
Obesity | 3.3 | 2.1 | 0.57 |
obsessive-compulsive disorder | 2.2 | 1.9 | 0.16 |
Osteoarthritis | 1.5 | 0.6 | 1.5 |
Osteoporosis | 1.2 | 0.3 | 3 |
Parkinson's Disease | 2.7 | 2.7 | 0 |
Polycystic ovary syndrome | 2.5 | 1.2 | 1.08 |
primary biliary cholangitis | 0 | 0 | |
Primary sclerosing cholangitis | 0.3 | 0.9 | -2 |
Psoriasis | 1.2 | 1.2 | 0 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.8 | 1.1 | 1.55 |
Rosacea | 0.5 | 0.5 | |
Schizophrenia | 0.9 | 0.6 | 0.5 |
scoliosis | 0.6 | 0.6 | 0 |
Sjögren syndrome | 1 | 0.6 | 0.67 |
Sleep Apnea | 0.3 | 0.6 | -1 |
Slow gastric motility / Gastroparesis | 1.2 | 1.2 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.9 | |
Stress / posttraumatic stress disorder | 0.9 | 0.3 | 2 |
Systemic Lupus Erythematosus | 2.1 | 0.3 | 6 |
Tic Disorder | 0.3 | 0.4 | -0.33 |
Tourette syndrome | 0.3 | -0.3 | |
Type 1 Diabetes | 1.8 | 0.6 | 2 |
Type 2 Diabetes | 3.3 | 1.6 | 1.06 |
Ulcerative colitis | 1.8 | 1.7 | 0.06 |
Unhealthy Ageing | 1.8 | 0.5 | 2.6 |
Vitiligo | 0.9 | 0.9 |